Thus, our new study, published in the Journal of Crohn’s and Colitis, investigates real world treatment patterns in both Crohn’s disease and ulcerative colitis.

The study is based on extensive analysis of the first decade after diagnosis, including differences in medication use across age, sex, and calendar year of diagnosis between 2003 and 2023. Thereby, it provides population-based estimates of real-world treatment patterns to both patients, clinicians, and healthcare systems. 

Interestingly, whereas advanced therapies dominate long-term treatment for Crohn's disease, 5‑ASA remains the mainstay of treatment for ulcerative colitis. Notably, in the tenth year after diagnosis, half of patients did not receive medical treatment at all.

Authors

Heidi Søgaard Christensen
Lone Larsen
Charlie W Lees
Martin Bøgsted
Tine Jess